SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc (Amendment)

SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc (Amendment)

Recent Analyst Ratings for $CNTA

$CNTA SEC Filings

$CNTA Press Releases

$CNTA Analyst Ratings

$CNTA Large Ownership Changes

$CNTA Financials

$CNTA Leadership Updates

$CNTA Market Insights

$CNTA Insider Trading

Recent Analyst Ratings for
$CNTA

$CNTA
SEC Filings

$CNTA
Press Releases

$CNTA
Analyst Ratings

$CNTA
Large Ownership Changes

$CNTA
Financials

$CNTA
Leadership Updates

$CNTA
Market Insights

$CNTA
Insider Trading

Chat with this insight

Centessa Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Centessa Pharmaceuticals plc

SEC Form 144 filed by Centessa Pharmaceuticals plc

Fastest customizable press release news feed in the world

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

This live feed shows all institutional transactions in real time.

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals upgraded by Morgan Stanley with a new price target

B. Riley Securities initiated coverage on Centessa Pharmaceuticals with a new price target

Oppenheimer initiated coverage on Centessa Pharmaceuticals with a new price target

Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc (Amendment)

Live finance-specific insights

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

Live Leadership Updates

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

Centessa Pharmaceuticals Announces Additions to Senior Leadership Team

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

Live Market Insights

Oppenheimer Initiates Coverage On Centessa Pharmaceuticals with Outperform Rating, Announces Price Target of $14

Morgan Stanley Maintains Equal-Weight on Centessa Pharmaceuticals, Raises Price Target to $11

Centessa Pharma Taps John Crowley, as CFO, Effective June 10

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Saha Saurabh exercised 32,023 units of Ordinary Shares at a strike of $5.84 and sold $585,419 worth of Ordinary Shares (32,023 units at $18.28) (SEC Form 4)

Chief Business Officer Weinhoff Gregory M sold $180,628 worth of Ordinary Shares (11,742 units at $15.38), decreasing direct ownership by 6% to 183,266 units (SEC Form 4)

Chief Executive Officer Saha Saurabh sold $863,727 worth of Ordinary Shares (55,000 units at $15.70), decreasing direct ownership by 8% to 630,661 units (SEC Form 4)

1/31/23 4:00:01 PM ET

$CNTA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CNTA alert in real time by email

SC 13G/A 1 d438876dsc13ga.htm SC 13G/A SC 13G/A

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

CENTESSA PHARMACEUTICALS PLC

(Name of Issuer)

Ordinary Shares, nominal value £0.002 per share

(Title of Class of Securities)

152309100 (for American Depositary Shares, each representing 1 Ordinary Share)

(CUSIP Number)

December 31, 2022

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 152309100		SCHEDULE 13G		Page 2 of 16

*	Calculated based upon 94,596,247 Ordinary Shares outstanding of the Issuer as of October 31, 2022, as set forth in the Issuer’s Form 10-Q for the period ended September 30, 2022, filed with the Securities and Exchange Commission on November 10, 2022.


CUSIP No. 152309100		SCHEDULE 13G		Page 3 of 16

*	Calculated based upon 94,596,247 Ordinary Shares outstanding of the Issuer as of October 31, 2022, as set forth in the Issuer’s Form 10-Q for the period ended September 30, 2022, filed with the Securities and Exchange Commission on November 10, 2022.


CUSIP No. 152309100		SCHEDULE 13G		Page 4 of 16

*	Calculated based upon 94,596,247 Ordinary Shares outstanding of the Issuer as of October 31, 2022, as set forth in the Issuer’s Form 10-Q for the period ended September 30, 2022, filed with the Securities and Exchange Commission on November 10, 2022.


CUSIP No. 152309100		SCHEDULE 13G		Page 5 of 16

*	Calculated based upon 94,596,247 Ordinary Shares outstanding of the Issuer as of October 31, 2022, as set forth in the Issuer’s Form 10-Q for the period ended September 30, 2022, filed with the Securities and Exchange Commission on November 10, 2022.


CUSIP No. 152309100		SCHEDULE 13G		Page 6 of 16

*	Calculated based upon 94,596,247 Ordinary Shares outstanding of the Issuer as of October 31, 2022, as set forth in the Issuer’s Form 10-Q for the period ended September 30, 2022, filed with the Securities and Exchange Commission on November 10, 2022.


CUSIP No. 152309100		SCHEDULE 13G		Page 7 of 16

*	Calculated based upon 94,596,247 Ordinary Shares outstanding of the Issuer as of October 31, 2022, as set forth in the Issuer’s Form 10-Q for the period ended September 30, 2022, filed with the Securities and Exchange Commission on November 10, 2022.


CUSIP No. 152309100		SCHEDULE 13G		Page 8 of 16

*	Calculated based upon 94,596,247 Ordinary Shares outstanding of the Issuer as of October 31, 2022, as set forth in the Issuer’s Form 10-Q for the period ended September 30, 2022, filed with the Securities and Exchange Commission on November 10, 2022.


CUSIP No. 152309100		SCHEDULE 13G		Page 9 of 16

*	Calculated based upon 94,596,247 Ordinary Shares outstanding of the Issuer as of October 31, 2022, as set forth in the Issuer’s Form 10-Q for the period ended September 30, 2022, filed with the Securities and Exchange Commission on November 10, 2022.


CUSIP No. 152309100		SCHEDULE 13G		Page 10 of 16

*	Calculated based upon 94,596,247 Ordinary Shares outstanding of the Issuer as of October 31, 2022, as set forth in the Issuer’s Form 10-Q for the period ended September 30, 2022, filed with the Securities and Exchange Commission on November 10, 2022.


CUSIP No. 152309100		SCHEDULE 13G		Page 11 of 16

*	Calculated based upon 94,596,247 Ordinary Shares outstanding of the Issuer as of October 31, 2022, as set forth in the Issuer’s Form 10-Q for the period ended September 30, 2022, filed with the Securities and Exchange Commission on November 10, 2022.


CUSIP No. 152309100		SCHEDULE 13G		Page 12 of 16

Item 1.

Issuer.

(a)

Name of Issuer:

Centessa Pharmaceuticals plc (the “Issuer”)

(b)

Address of Issuer’s Principal Executive Offices:

3^rd Floor, 1 Ashley Road

1 Ashley Road, Altrincham Cheshire WA14 2DT United Kingdom

Item 2.

Filing Person.

Item 2 (a) – (c). Name of Persons Filing; Address; Citizenship:

(i)

Medicxi Growth I LP (“Growth I”), a Jersey limited partnership;

(ii)

Medicxi Growth Co-Invest I LP (“Growth Co-Invest I”), a Jersey limited partnership;

(iii)

Medicxi Growth I GP Limited (“Growth I GP”), a Jersey limited liability company, which is the sole managing general partner of Growth I and Growth Co-Invest I;

(iv)

Medicxi Ventures I LP (“Ventures I”), a Jersey limited partnership;

(v)

Medicxi Co-Invest I LP (“Co-Invest I”), a Jersey limited partnership;

(vi)

Medicxi Ventures I GP Limited (“Ventures I GP”), a Jersey limited liability company, which is the sole managing general partner of Ventures I and Co-Invest I;

(vii)

Medicxi Secondary I LP (“Secondary I”), a Jersey limited partnership;

(viii)

Medicxi Secondary Co-Invest I LP (“Secondary Co-Invest I” and, together with Growth I, Growth Co-Invest I, Ventures I, Co-Invest I and Secondary I, the “Medicxi Funds”), a Jersey limited partnership;

(ix)

Medicxi Secondary I GP Limited (“Secondary I GP”), a Jersey limited liability company, which is the sole managing general partner of Secondary I and Secondary Co-Invest I; and

(x)

Medicxi Ventures Management (Jersey) Limited (“Medicxi Manager”), a Jersey limited liability company, which is the sole manager of the Medicxi Funds.

Growth I, Growth Co-Invest I, Growth I GP, Ventures I, Co-Invest I, Ventures I GP, Secondary I, Secondary Co-Invest I, Secondary I GP and Medicxi Manager are sometimes individually referred to herein as a “Reporting Person” and collectively as the “Reporting Persons.”

The address of the principal business office of each of the Reporting Persons is c/o Intertrust Fund Services (Jersey) Limited, 44 Esplanade, St. Helier, Jersey JE4 9WG.

Medicxi Ventures (UK) LLP and Medicxi Ventures (Jersey) Limited act as sub-advisers to Index Ventures Life VI (Jersey) Limited, which acts as the adviser to Index Ventures Life VI (Jersey) LP, and as such, Index Ventures Life VI and Yucca (Jersey) SLP, each of which hold Ordinary Shares as of the date hereof, and the Medicxi Funds may be deemed to be members of a “group” as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended. The share ownership reported by the Medicxi Funds does not include any shares beneficially owned by Index Ventures Life VI (Jersey) LP and Yucca (Jersey) SLP, and each of the Medicxi Funds and their affiliates disclaim beneficial ownership of the securities beneficially owned by Index Ventures Life VI (Jersey) LP, Yucca (Jersey) SLP and their affiliates.

(d) Title of Class of Securities:

Ordinary Shares, nominal value £0.002 per share (the “Ordinary Shares”)

(e) CUSIP Number:

152309100


CUSIP No. 152309100		SCHEDULE 13G		Page 13 of 16

Item 3.

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:


(a)	☐	Broker or dealer registered under Section 15 of the Act;

(b)	☐	Bank as defined in Section 3(a)(6) of the Act;

(c)	☐	Insurance company as defined in Section 3(a)(19) of the Act;

(d)	☐	Investment company registered under Section 8 of the Investment Company Act of 1940;

(e)	☐	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

(j)	☐	A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

	If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4.

Ownership.


(a) and (b)	Amount beneficially owned:

	(i)	Growth I directly owns 3,936,970 Ordinary Shares, representing approximately 4.2% of the outstanding Ordinary Shares.

	(ii)	Growth Co-Invest I directly owns 93,526 Ordinary Shares, representing approximately 0.1% of the outstanding Ordinary Shares.

	(iii)	Growth I GP, as the managing general partner of Growth I and Growth Co-Invest I, may be deemed to beneficially own the Ordinary Shares held directly by Growth I and Growth Co-Invest I.

	(iv)	Ventures I directly beneficially owns 4,398,519 Ordinary Shares, representing approximately 4.6% of the outstanding Ordinary Shares.

	(v)	Co-Invest I directly beneficially owns 55,677 Ordinary Shares, representing less than 0.1% of the outstanding Ordinary Shares.

	(vi)	Ventures I GP, as the managing general partner of Ventures I and Co-Invest I, may be deemed to beneficially own the Ordinary Shares held directly by Ventures I and Co-Invest I.

	(vii)	Secondary I directly beneficially owns 11,197,303 Ordinary Shares, representing approximately 11.8% of the outstanding Ordinary Shares.

	(viii)	Secondary Co-Invest I directly beneficially owns 281,162 Ordinary Shares, representing approximately 0.3% of the outstanding Ordinary Shares.

	(ix)	Secondary I GP, as the managing general partner of Secondary I and Secondary Co-Invest I, may be deemed to beneficially own the Ordinary Shares held directly by Secondary I and Secondary Co-Invest I.

	(x)	Medicxi Manager, as manager of the Medicxi Funds, may be deemed to beneficially own the shares held directly by the Medicxi Funds.


CUSIP No. 152309100		SCHEDULE 13G		Page 14 of 16

(c)	Number of shares as to which such person has:


	Number of Ordinary Shares
Reporting Person	(i)		(ii)		(iii)		(iv)
Growth I		3,936,970		0		3,936,970		0
Growth Co-Invest I		93,526		0		93,526		0
Growth I GP		4,030,496		0		4,030,496		0
Ventures I		4,398,519		0		4,398,519		0
Co-Invest I		55,677		0		55,677		0
Ventures I GP		4,454,196		0		4,454,196		0
Secondary I		11,197,303		0		11,197,303		0
Secondary Co-Invest I		281,162		0		281,162		0
Secondary I GP		11,478,465		0		11,478,465		0
Medicxi Manager		19,963,157		0		19,963,157		0

(i) Sole power to vote or direct the vote

(ii) Shared power to vote or to direct the vote

(iii) Sole power to dispose or to direct the disposition of

(iv) Shared power to dispose or to direct the disposition of


Item 5.		Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

Item 6.		Ownership of More than Five Percent on Behalf of Another Person. Not applicable.

Item 7.		Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable.

Item 8.		Identification and Classification of Members of the Group. Not applicable.

Item 9.		Notice of Dissolution of Group. Not applicable.

Item 10.		Certification. Not applicable.


CUSIP No. 152309100		SCHEDULE 13G		Page 15 of 16

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

Dated: January 31, 2023


MEDICXI GROWTH I LP

By:		Medicxi Ventures Management (Jersey) Limited, its sole manager

By:		/s/ Nigel Crocker
		Name: Nigel Crocker Title: Director

MEDICXI GROWTH CO-INVEST I LP

By:		Medicxi Ventures Management (Jersey) Limited, its sole manager

By:		/s/ Nigel Crocker
		Name: Nigel Crocker
		Title: Director

MEDICXI GROWTH I GP LIMITED

By:		/s/ Nigel Crocker
		Name: Nigel Crocker
		Title: Director

MEDICXI VENTURES I LP

By:		Medicxi Ventures Management (Jersey) Limited, its sole manager

By:		/s/ Nigel Crocker
		Name: Nigel Crocker Title: Director

MEDICXI CO-INVEST I LP

By:		Medicxi Ventures Management (Jersey) Limited, its sole manager

By:		/s/ Nigel Crocker
		Name: Nigel Crocker Title: Director


CUSIP No. 152309100		SCHEDULE 13G		Page 16 of 16


MEDICXI VENTURES I GP LIMITED

By:		/s/ Nigel Crocker
		Name: Nigel Crocker Title: Director

MEDICXI SECONDARY I LP

By:		Medicxi Ventures Management (Jersey) Limited, its sole manager

By:		/s/ Nigel Crocker
		Name: Nigel Crocker Title: Director

MEDICXI SECONDARY CO-INVEST I LP

By:		Medicxi Ventures Management (Jersey) Limited, its sole manager

By:		/s/ Nigel Crocker
		Name: Nigel Crocker Title: Director

MEDICXI SECONDARY I GP LIMITED

By:		/s/ Nigel Crocker
		Name: Nigel Crocker Title: Director

MEDICXI VENTURES MANAGEMENT (JERSEY) LIMITED

/s/ Nigel Crocker
Name: Nigel Crocker Title: Director

Get the next $CNTA alert in real time by email

Date	Price Target	Rating	Analyst
9/20/2024	$11.00 → $26.00	Equal-Weight → Overweight	Morgan Stanley
9/19/2024	$33.00	Buy	B. Riley Securities
7/18/2024	$14.00	Outperform	Oppenheimer
11/15/2023	$4.00 → $11.00	Hold → Buy	Jefferies
10/26/2023	$4.00 → $8.00	Underweight → Equal-Weight	Morgan Stanley
6/21/2023		Outperform	Evercore ISI
6/12/2023	$9.00	Buy	Guggenheim
3/17/2023	$6.00	Outperform	SVB Securities

Names of Reporting Persons.

  I.R.S. Identification Nos. of above persons (entities only)

  Medicxi Growth I LP

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐ (b) ☒

SEC Use Only

Citizenship or Place of Organization

Jersey